Improving HER2 testing reproducibility in HER2-low breast cancer
Cancer Drug Resistance, 2022 HER2 is a pillar biomarker in breast cancer, and it is assessed by immunohistochemistry (IHC) using a three-tier scoring system and reflex in situ hybridization (ISH) for IHC score 2+. Novel HER2-directed antibody-drug conjugates have demonstrated significant antitumor activity in breast cancers with low levels of HER2 expression, i.e.
Sajjadi E. +3 more
openaire +2 more sources
Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer [PDF]
, 2015 Neoadjuvant chemotherapy plus trastuzumab (NCT) increases the rate of pathological complete response (pCR) and event-free survival (EFS) compared to neoadjuvant chemotherapy (NC) alone in women with HER2 positive breast cancer (BC).
Ades, F +16 more
core +2 more sources
DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. [PDF]
, 2017 Veliparib combined with carboplatin (VC) was an experimental regimen evaluated in the biomarker-rich neoadjuvant I-SPY 2 trial for breast cancer. VC showed improved efficacy in the triple negative signature.
Berry, Don +20 more
core +2 more sources
Genomic aberrations in normal tissue adjacent to HER2-amplified breast cancers: field cancerization or contaminating tumor cells? [PDF]
, 2012 Field cancerization effects as well as isolated tumor cell foci extending well beyond the invasive tumor margin have been described previously to account for local recurrence rates following breast conserving surgery despite adequate surgical margins and
Benz, Christopher C +8 more
core +2 more sources
MiR-18a-5p attenuates HER2-positive breast cancer development by regulating PI3K/AKT pathway
Cancer Biology & Therapy, 2023 Objective: Human epidermal growth factor receptor 2 positive (HER2+) breast cancer (BC) is associated with poor prognosis. This study aimed to elucidate the role of miR−18a−5p in regulation of HER2+-BC progression along with its mechanism of action ...
Yongjun Liu, Hua Yang
doaj +1 more source
Current aspects of systematics, diagnosis and treatment of breast cancer
Опухоли женской репродуктивной системы, 2022 The purpose of the study was to mine, compile and analyze the published data on breast cancer (BC) systematization, diagnosis and treatment. In the current review, modern approaches in BC subtypes diagnosis based on genomic profiling, miRNA expression ...
D. N. Strunkin +4 more
doaj +1 more source
Characterising the tumour morphological response to therapeutic intervention:an ex vivo model [PDF]
, 2012 In cancer, morphological assessment of histological tissue samples is a fundamental part of both diagnosis and prognosis. Image analysis offers opportunities to support that assessment through quantitative metrics of morphology.
Bown, James L. +6 more
core +5 more sources
GLUCOSE LEVELS OF PLEURAL EFFUSION FLUID AND HER2 STATUS IN PLEURAL-METASTATIC BREAST CANCER
Majalah Biomorfologi, 2023 Highlights • Patients with breast cancer who have distant metastases are frequently impacted by pleural effusion. • HER2 status was found to be substantially correlated with glucose levels in pleural effusion fluid.
Muhammad Dhanny Irawan +2 more
doaj +1 more source
Nanoparticles for live cell microscopy: A surface-enhanced Raman scattering perspective. [PDF]
, 2017 Surface enhanced Raman scattering (SERS) nanoparticles are an attractive alternative to fluorescent probes for biological labeling because of their photostability and multiplexing capabilities.
Candas, Demet +7 more
core +1 more source
Indian Journal of Pathology and Microbiology, 2022 Background: Colorectal cancer (CRC) is the third most commonly occurring cancer in men and the second most common cancer in women. Despite advances in surgical techniques and chemotherapeutic regimens, CRC continues to be one of the main causes of cancer-
Ismail Saygin, Emel Cakir
doaj +1 more source